Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Embelin Ameliorate Testosterone-Induced Prostatic Hyperplasia in Rats

Embelin Ameliorate Testosterone-Induced Prostatic Hyperplasia in Rats Embelin, is a naturally occurring alkyl substituted hydroxyl benzoquinone and a major constituent from all the parts of Embelia ribes. It possesses antitumor, anti-inflammatory, antioxidant, analgesic activities and also has the ability to decrease testosterone levels. The present study was designed to determine the effect of embelin on testosterone-induced benign prostatic hyperplasia (BPH) in rats. Male Wistar rats were randomly divided into six groups and treated with either embelin (5 and 10 mg/kg), finasteride (1 mg/kg) or vehicle. After above mentioned treatment, testosterone (3 mg/kg; subcutaneously) was administration for 28 days, to induce BPH. On the day 29, blood samples were collected from the retro-orbital plexus. After blood sample collection, animals were sacrificed and prostates were immediately dissected out for weight measurement, biochemical estimations and histopathological studies. Prostatic serum acid phosphatase (PSAP) and prostate-specific antigen (PSA) were estimated. Administration of testosterone leads to significant increase in prosthetic weight, PSAP, PSA and lipid peroxidation levels and decrease in the antioxidant status. Moreover, histopathological abnormalities in the prostatic tissue were also found in these animals. Treatment with both the doses of embelin and finasteride significantly reversed the changes produced by testosterone. The authors conclude that antioxidant and anti-inflammatory properties of embelin are responsible for its protection against testosterone-induced BPH. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Proceedings of the National Academy of Sciences, India Section B: Biological Sciences Springer Journals

Loading next page...
 
/lp/springer-journals/embelin-ameliorate-testosterone-induced-prostatic-hyperplasia-in-rats-Y0gYdnST6n

References (29)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The National Academy of Sciences, India
Subject
Life Sciences; Life Sciences, general; Behavioral Sciences; Plant Biochemistry; Nucleic Acid Chemistry
ISSN
0369-8211
eISSN
2250-1746
DOI
10.1007/s40011-017-0843-2
Publisher site
See Article on Publisher Site

Abstract

Embelin, is a naturally occurring alkyl substituted hydroxyl benzoquinone and a major constituent from all the parts of Embelia ribes. It possesses antitumor, anti-inflammatory, antioxidant, analgesic activities and also has the ability to decrease testosterone levels. The present study was designed to determine the effect of embelin on testosterone-induced benign prostatic hyperplasia (BPH) in rats. Male Wistar rats were randomly divided into six groups and treated with either embelin (5 and 10 mg/kg), finasteride (1 mg/kg) or vehicle. After above mentioned treatment, testosterone (3 mg/kg; subcutaneously) was administration for 28 days, to induce BPH. On the day 29, blood samples were collected from the retro-orbital plexus. After blood sample collection, animals were sacrificed and prostates were immediately dissected out for weight measurement, biochemical estimations and histopathological studies. Prostatic serum acid phosphatase (PSAP) and prostate-specific antigen (PSA) were estimated. Administration of testosterone leads to significant increase in prosthetic weight, PSAP, PSA and lipid peroxidation levels and decrease in the antioxidant status. Moreover, histopathological abnormalities in the prostatic tissue were also found in these animals. Treatment with both the doses of embelin and finasteride significantly reversed the changes produced by testosterone. The authors conclude that antioxidant and anti-inflammatory properties of embelin are responsible for its protection against testosterone-induced BPH.

Journal

Proceedings of the National Academy of Sciences, India Section B: Biological SciencesSpringer Journals

Published: Jan 19, 2017

There are no references for this article.